CA2745341C - Means and methods for activating vagus nerve - Google Patents

Means and methods for activating vagus nerve Download PDF

Info

Publication number
CA2745341C
CA2745341C CA2745341A CA2745341A CA2745341C CA 2745341 C CA2745341 C CA 2745341C CA 2745341 A CA2745341 A CA 2745341A CA 2745341 A CA2745341 A CA 2745341A CA 2745341 C CA2745341 C CA 2745341C
Authority
CA
Canada
Prior art keywords
lactic acid
food
bacterial cells
lactobacillus
vagus nerve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2745341A
Other languages
English (en)
French (fr)
Other versions
CA2745341A1 (en
Inventor
Daisuke Sawada
Shigeru Fujiwara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Group Holdings Ltd
Original Assignee
Asahi Group Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Group Holdings Ltd filed Critical Asahi Group Holdings Ltd
Publication of CA2745341A1 publication Critical patent/CA2745341A1/en
Application granted granted Critical
Publication of CA2745341C publication Critical patent/CA2745341C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
CA2745341A 2010-07-07 2011-07-06 Means and methods for activating vagus nerve Active CA2745341C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010-154893 2010-07-07
JP2010154893A JP5923238B2 (ja) 2010-07-07 2010-07-07 迷走神経活性化剤

Publications (2)

Publication Number Publication Date
CA2745341A1 CA2745341A1 (en) 2012-01-07
CA2745341C true CA2745341C (en) 2018-01-16

Family

ID=45438733

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2745341A Active CA2745341C (en) 2010-07-07 2011-07-06 Means and methods for activating vagus nerve

Country Status (3)

Country Link
US (2) US20120009163A1 (enExample)
JP (1) JP5923238B2 (enExample)
CA (1) CA2745341C (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5943342B2 (ja) * 2012-03-02 2016-07-05 国立研究開発法人産業技術総合研究所 概日リズム改善剤
JP6067292B2 (ja) * 2012-03-19 2017-01-25 サッポロビール株式会社 セロトニン分泌促進剤
EP2881459B1 (en) * 2012-07-31 2025-06-25 Kaneka Corporation Novel Enterococcus faecium Strains
CA2890507A1 (en) * 2012-11-16 2014-05-22 Calpis Co., Ltd. Agent for alleviating stress-induced bowel disorder containing specific lactobacillus gasseri strain or treated product threof
JP6214162B2 (ja) * 2012-11-16 2017-10-18 アサヒグループホールディングス株式会社 新規の低温耐性ラクトバチルス・ガセリ株
JP2014101288A (ja) * 2012-11-16 2014-06-05 Calpis Co Ltd ストレス性腸障害の抑制剤
JP6053466B2 (ja) * 2012-11-16 2016-12-27 アサヒグループホールディングス株式会社 ストレス性下痢の抑制剤
US10039798B2 (en) * 2013-11-13 2018-08-07 In Ingredients, Inc. Extracts of rosemary or hemerocallis fulva and methods of using same to promote circadian rhythm
EP3124031B1 (en) * 2014-03-25 2020-12-30 Kabushiki Kaisha Yakult Honsha Sleep quality improver
KR101720681B1 (ko) * 2014-11-26 2017-04-03 고려대학교 산학협력단 호프 추출물을 포함하는 수면 촉진용 조성물
WO2017033925A1 (ja) * 2015-08-24 2017-03-02 株式会社ヤクルト本社 酪酸産生菌
JP6654639B2 (ja) * 2015-09-18 2020-02-26 国立大学法人徳島大学 血中トリプトファン濃度上昇抑制剤
JP6820340B2 (ja) * 2015-12-17 2021-01-27 シージェイ チェルジェダン コーポレイション 腸内生存率が高められた乳酸菌のコーティング方法
US10925906B2 (en) 2016-04-13 2021-02-23 Meiji Co., Ltd. Composition for improving brain function for neonates
CN108495558A (zh) * 2016-04-20 2018-09-04 株式会社明治 疲劳感改善用发酵乳
AU2017287987B2 (en) 2016-06-30 2024-08-01 Asahi Group Holdings, Ltd. Cartilage regeneration facilitating composition
JP6923883B2 (ja) * 2016-06-30 2021-08-25 アサヒグループホールディングス株式会社 栄養状態改善に使用するための組成物
JP6994116B2 (ja) * 2018-02-02 2022-02-04 コバイオラブス，インコーポレーテッド ラクトバチルスプランタルムｋｂｌ３９６菌株およびその用途
JP2019156721A (ja) * 2018-03-07 2019-09-19 フタムラ化学株式会社 血流改善用可食組成物
US20210352925A1 (en) * 2019-02-04 2021-11-18 N.V. Nutricia Fermented formula with non digestible oligosaccharides for sleep improvement
JP7369992B2 (ja) * 2019-05-13 2023-10-27 株式会社明治 自律神経機能改善用の発酵乳
CN111034761A (zh) * 2019-12-23 2020-04-21 江西普正制药股份有限公司 一种杜仲饼干及其制备方法
JP2021123561A (ja) * 2020-02-05 2021-08-30 雪印メグミルク株式会社 睡眠促進用組成物及び組成物を含む食品、医薬品、飼料
WO2021157435A1 (ja) * 2020-02-05 2021-08-12 雪印メグミルク株式会社 睡眠促進用組成物及び組成物を含む食品、医薬品、飼料
JP2021123562A (ja) * 2020-02-05 2021-08-30 雪印メグミルク株式会社 睡眠促進用組成物及び組成物を含む食品、医薬品、飼料
JP7593740B2 (ja) * 2020-03-02 2024-12-03 株式会社明治 睡眠の質改善用組成物、全体的健康感改善用組成物および活力向上用組成物
CN111826324A (zh) * 2020-08-05 2020-10-27 厦门惠盈动物科技有限公司 一种鼠李糖乳杆菌菌粉的制备方法
CN112106704A (zh) * 2020-10-28 2020-12-22 广东梁氏水产种业有限公司 蛭弧菌用于提高翘嘴鳜人工饲料驯食率的用途
WO2022115907A1 (en) * 2020-12-01 2022-06-09 Servatus Ltd Methods for improving sleep quality
JPWO2023234166A1 (enExample) * 2022-06-01 2023-12-07
TW202506147A (zh) * 2023-04-28 2025-02-16 日商東亞藥品工業股份有限公司 神經幹細胞之增殖、分化、成熟之促進、小神經膠質細胞之活化促進及星狀細胞之活化促進用組成物、以及記憶力及/或學習能力之維持及/或提升用組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3046303B1 (ja) * 1999-06-24 2000-05-29 明治乳業株式会社 Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ除菌性飲食品
US6444203B2 (en) * 1999-12-20 2002-09-03 Compagnie Gervais Danone Administering bacteria to improve sleep
USRE48652E1 (en) * 2006-08-04 2021-07-20 Bioneer Corporation Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
JP2008214253A (ja) * 2007-03-02 2008-09-18 Snow Brand Milk Prod Co Ltd 内臓脂肪減少剤
EP2143427A1 (en) * 2007-03-30 2010-01-13 Suntory Holdings Limited Medicinal composition, food or drink having effect of enhancing parasympathetic nervous actions
US8259163B2 (en) * 2008-03-07 2012-09-04 Intellectual Ventures Holding 67 Llc Display with built in 3D sensing
AU2009319257B2 (en) * 2008-11-03 2014-10-09 Société des Produits Nestlé S.A. A nutritional composition comprising probiotics and improving sleep patterns
JP5155961B2 (ja) * 2009-07-17 2013-03-06 雪印メグミルク株式会社 加齢に伴う代謝異常症の予防・改善・治療剤

Also Published As

Publication number Publication date
JP2012017282A (ja) 2012-01-26
US20120009163A1 (en) 2012-01-12
CA2745341A1 (en) 2012-01-07
US20130336943A1 (en) 2013-12-19
JP5923238B2 (ja) 2016-05-24

Similar Documents

Publication Publication Date Title
CA2745341C (en) Means and methods for activating vagus nerve
US9468657B2 (en) Lactic acid bacterium agent for improving lipid metabolism
JP5686680B2 (ja) 乳酸菌発酵によるカゼイン由来ペプチドの製造方法
JP6165185B2 (ja) 乳酸菌又はその処理物を含む脂質代謝及び／又は糖代謝改善剤
AU2017287989B2 (en) Composition for use in improvement of nutritional state
EP3479837B1 (en) Renal anemia ameliorating composition
JP5950993B2 (ja) 迷走神経活性化剤
US20130004475A1 (en) Agent for increasing bifidobacteria and reducing the decrease of bifidobacteria in large intestine
EP3479836B1 (en) Cartilage regeneration facilitating composition
AU2015201076B2 (en) Lipid metabolism-improving agent

Legal Events

Date Code Title Description
EEER Examination request